For example, I think that, in evidence to the Parliament’s Health and Sport Committee, Parkinson’s UK indicated a concern about the availability of medicines. I have heard from the pharmaceutical sector on many occasions that, because of the difficulties of leaving the European Medicines Agency, there will be issues ...